CN Patent

CN101616895A — 作为蛋白激酶抑制剂的化合物和组合物

Assigned to IRM LLC · Expires 2009-12-30 · 16y expired

What this patent protects

本发明提供新的嘧啶和吡啶衍生物及其药物组合物，和使用这类化合物的方法。例如本发明的嘧啶和吡啶衍生物可用于治疗、改善或预防响应于退行发育淋巴瘤激酶(ALK)活性、粘着斑激酶(FAK)、ζ链相关蛋白激酶70(ZAP－70)、胰岛素样生长因子(IGF－1R)或其组合的抑制的病症。

USPTO Abstract

本发明提供新的嘧啶和吡啶衍生物及其药物组合物，和使用这类化合物的方法。例如本发明的嘧啶和吡啶衍生物可用于治疗、改善或预防响应于退行发育淋巴瘤激酶(ALK)活性、粘着斑激酶(FAK)、ζ链相关蛋白激酶70(ZAP－70)、胰岛素样生长因子(IGF－1R)或其组合的抑制的病症。

Drugs covered by this patent

Patent Metadata

Patent number
CN101616895A
Jurisdiction
CN
Classification
—
Expires
2009-12-30
Drug substance claim
No
Drug product claim
No
Assignee
IRM LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.